美国国家癌症研究院最新头颈癌临床试验结果
Head and Neck Cancer Tr ial Results
(http://www.cancer.gov/clinicaltrials/results/head- and- neck)
1. Cetuximab (Erbitux!) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
(Posted: 06/26/2007) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received
cetuximab (Erbitux!) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy
alone, according to findings presented at the 2007 ASCO meeting in Chicago.
2. Chemotherapy During Radiation Treatment Improves Outcomes in Nasopharyngeal Cancer
(Posted: 02/15/2006) - In this meta- analysis, researchers found that chemotherapy given during standard radiation treatment
for nasopharyngeal cancer reduced the risk of death, and also of cancer recurrence, according to the Jan. 1, 2006, issue of the
International Journal of Radiation Oncology, Biology, Physics.
3. Cetuximab (Erbitux!) Plus Radiation Beneficial for Patients with Head and Neck Cancer
(Posted: 06/05/2004, Updated: 02/13/2006) - Compared to radiation alone, cetuximab plus radiation therapy can nearly
double the median survival in patients with a certain kind of head and neck cancer that has not spread to other parts of the body,
according to the Feb. 9, 2006, issue of the New England Journal of Medicine.
4. Oxaliplatin (Eloxatin!) Plus Radiation Superior in Advanced Nasopharyngeal Cancer
(Posted: 11/02/2005) - Patients with locally advanced nasopharyngeal cancer who received oxaliplatin (Eloxatin!) during
their initial treatment with radiotherapy did significantly better than those receiving radiation alone, according to a report published
online Oct. 17, 2005, by the Journal of Clinical Oncology.
5. Vitamin E Does Not Help Head and Neck Cancer Patients
(Posted: 08/01/2005) - A large randomized study of patients treated with radiation therapy for head and neck cancer found
that vitamin E supplements did not prevent the occurrence of second primary tumors and may be associated with an increased risk
of cancer recurrence. The results demonstrate that vitamin E supplements are not beneficial to patients with stage I or II head and
neck cancer.
6. Frozen Glove Reduces Skin and Nail Damage from Docetaxel Chemotherapy
(Posted: 08/01/2005) - Patients who wore an experimental “frozen glove”to keep their hands very cold during intravenous
chemotherapy with docetaxel (Taxotere!) had much less subsequent damage to the nails and skin of their hands, according to a
study published in the July 1, 2005, issue of the Journal of Clinical Oncology.
7. Docetaxel (Taxotere!) Before Radiation Extends Survival in Patients with Head and Neck Cancer
(Posted: 06/05/2004, Reviewed: 11/27/2007) - In a phase III study of patients with inoperable head and neck cancer, a
multidrug chemotherapy regimen including the drug docetaxel (Taxotere!) that was given before radiation extended patients '
survival by about four months, with fewer side effects, compared to standard therapy.
8. Combined Therapy May Offer Advantage in Head and Neck Cancer
(Posted: 06/02/2004) - Patients with head and neck cancer who were treated with chemotherapy in addition to radiation after
surgery had fewer recurrences of disease and longer disease- free survival than patients who were treated with radiation alone after
surgery, two randomized clinical trials have found.
9. Chemotherapy and Radiation Together May Help Save Voicebox
(Posted: 05/14/2002, Reviewed: 04/05/2005) - People with cancer of the larynx often face laryngectomy - - surgery to remove
the voicebox - - to help stop the spread of the cancer. Now, a new study shows that giving chemotherapy and radiation therapy
together can put off the need for a laryngectomy and preserve use of the voicebox longer than the currently established practice of
giving chemotherapy followed by radiation.